Knowledge & insights

banner-image
banner-image
banner-image

 

Knowledge & insights

banner-image
banner-image
banner-image

Workplace Policies for Prescription Drugs

Workplace Policies for Prescription Drugs

This information is provided for educational purposes only. Reader retains full responsibility for the use of the information contained herein.

The nonmedical use of prescription psychotherapeutic drugs – and of pain relievers in particular – is now second only to marijuana use among the nation’s most prevalent drugs of choice.

The Nature of the Problem

Americans are in pain and a growing number are not hesitant about taking medications to cope with that pain. The use of prescription drugs to treat medical and mental disorders has risen substantially in the United States in recent years.

From 1960 to 2019, consumer expenditures on prescription drugs rose from $2.7 billion to $360.3 billion.1 The nonmedical use of prescription psychotherapeutic drugs – and of pain relievers in particular – is now second only to marijuana use among the nation’s most prevalent drugs of choice.2

Develop a Well-Written and Clear Policy

Although no drug free workplace can guarantee that there will be no drug use or abuse, the investment in a robust deterrence and detection program is an excellent investment for risk-averse employers. Employers should include a prescription medication disclosure provision in their workplace policy, especially in safety-sensitive workplaces. Prescription drug disclosure should be limited to those medications with impairing effects.

Take the following case as an example of a detailed and well-written drug-free workplace policy that includes a prescription drug disclosure policy. An automotive systems company implemented a new drug testing policy prohibiting employees from “being impaired by or under the influence” of alcohol, illegal drugs, or legal drugs—including prescription medications and over-the-counter drugs—to the extent that employees’ use of such drugs endangered others or affected their job performance.

To implement this policy, the automotive systems company instructed its third-party drug testing facility to test for an expanded panel — including some substances that appear in prescription medications. If an employee tested positive for any of these substances, the company was notified and the employee was sent home. Following that, a Medical Review Officer (MRO) questioned the employees and changed results to “negative” if the employee had a valid prescription that explained the positive result, forwarding the change of status to the compan6. The company then instructed these employees to bring their medications to a supervisor at the company. If the label of the medication was packaged with warnings against operating machinery, the employee was then instructed that they must discontinue use of the medication or be terminated. The employees were not questioned about their medical conditions.

The company refrained from asking any questions about the employees’ medical conditions. The drug tests revealed only the prohibited chemicals and not the medications themselves, and it limited its inquiries into medications to those with machine operation warnings. The company appeared to go to lengths to prevent knowledge or consideration of the medical conditions of its employees, and instead focused its policy on the effects of certain chemicals on employees’ work.3

Implementing a Program

Although no drug free workplace can truly guarantee that there will be no drug use or abuse, the investment in a robust deterrence and detection program is an excellent investment for risk adverse employers. Implementing a prescription drug disclosure program, considering the size of today’s prescription drug abuse epidemic, helps employers protect themselves from liability while promoting a safe workplace. Safety not only protects your employees and customers, it protects your bottom line.

References

  1. “Prescription drug expenditure in the United States from 1960 to 2019.” Statistahttps://www.statista.com/statistics/184914/prescription-drug-expenditures-in-the-us-since-1960/. Accessed 28 May 2020.
  2. Lipari, Rachel N, Ph.D., Van Horn, Struther L., M.A., Hughes, Arthur, M.S., Williams, Matthew, Ph.D. “State and Substate Estimates of Nonmedical Use of Prescription Pain Relievers.” The CBHSQ Report, The Substance Abuse and Mental Health Services Administration (SAMHSA),  https://www.samhsa.gov/data/sites/default/files/report_3187/ShortReport-3187.html. Accessed 28 May 2020.
  3. Johnson, Marjorie, J.D. “Plant-wide testing for chemicals found in some prescription meds arguably a ‘medical exam.” Wolters Kluwerhttp://www.employmentlawdaily.com/index.php/news/plant-wide-testing-for-chemicals-found-in-some-prescription-meds-arguably-a-medical-exam/. Accessed 28 May 2020.

Select a topic

Related Articles

©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy.

Abbott - A Global Leader in Toxicology.